

Verification statement

To the stakeholders of Hikma Pharmaceuticals PLC

EcoAct was engaged by Hikma Pharmaceuticals PLC to provide independent third-party verification, to a reasonable level, of its direct (Scope 1) and indirect (Scope 2 and selected Scope 3) greenhouse gas emissions, as detailed in the company's carbon footprint reported in its 2022 Annual Report for the period 1st January to 31st December 2022.

Verified emissions by scope include:

- Scope 1 emissions – Combustion of gaseous fuels (natural gas, diesel, petrol and LPG), Fugitive refrigerant gases
- Scope 2 emissions – Purchased electricity consumption (location and market-based)
- Scope 3 emissions – Selected Scope 3 emissions including Water, Waste, Fuel and energy-related activities (not included in Scope 1 or Scope 2) and emissions associated with working from home and commuting.

Based on the data and information provided by Hikma and the processes and procedures followed, it is EcoAct's verification opinion that the following GHG emissions totals are fairly stated and free from material error:

<i>Hikma Carbon Emissions sources</i>	<i>2022 Emissions (tCO₂e)</i>
Scope 1 Emissions	43,012.4
Scope 2 Emissions (location-based)	81,578.5
Scope 2 Emissions (market-based – exc. RECs)	80,132.4
Scope 2 Emissions (market-based – inc. RECs)	65,462.1
Total Scope 1 & 2 (Location-Based)	124,590.9
Scope 3 Emissions (waste, water, well-to-tank, home working & commuting)	46,167.9
Total tCO₂e Scope 1,2 and 3 (location-based)	170,758.8

The full verification statement can be found here www.hikma.com/sustainability.